Molecular therapy for Bone disorders: MiR-1827 inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via down-regulation of its target gene, 8/February/2017, 8.33 am

Life-extension therapy: Hesperitin, found in Citrus fruits, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 7/February/2017, 11.01 pm
February 7, 2017
Natural product therapy for pulmonary arterial hypertension: EGCG (Epigallocatechin-3-gallate), one of the main components of Green tea, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 8/February/2017, 8.56 am
February 8, 2017
Show all

Introduction: What they say

A study from the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA has reported that “miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.”

This study was published in the June 25, 2014 Nature  [I.F >42] by Prof. Wan Y, Krzeszinski and others from  the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.


What we say:

On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: MiR-1827  inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene


From Research findings to Therapeutic utility

MiR-1827, by down-regulating its target gene, it may suppress the expression of Tgif2. Thereby, it may inhibit the progression of Osteoporosis and bone metastasis. 

price-5

[easy_payment currency=”USD”]

Thus, pharmacological formulations encompassing “MiR-1827  or its activators or MiR-1827  activator plus any of the known compounds that are in use to treat osteoporosis” can be used to inhibit osteoporosis and bone metastasis.


Details of the research findings: 

Idea Formulated (with experimental evidence) by: Dr L Boominathan PhD

Undisclosed mechanistic information: How MiR-1827  suppresses the expression of Tgif2

Amount: $5#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

#Research cooperation

For purchase & payment details, you may reach us at admin@genomediscovery.org


 References:

CitationBoominathan, L., Molecular therapy for Bone disorders: MiR-1827 inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via down-regulation of its target gene, 8/February/2017, 8.33 am., Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com/

Comments are closed.